LID.L Regulatory News (LID)

14 Feb 2005 07:00

14th February 2005 LiDCO GROUP PLC NOTICE OF MAJOR CLINICAL TRIAL RESULTS & PRELIMINARY RESULTS LiDCO, the cardiovascular monitoring company announces that the results of amajor trial using LiDCO's technology to increase oxygen delivery in surgerypatients at St George's Hospital, London, which concluded in September 2004,will be presented during the 25th International Symposium on Intensive Care andEmergency Medicine in Brussels (21st to 25th March). This meeting is one of theyear's most important gatherings of the international intensive care community.The trial quantified the effect of increased oxygen delivery (Goal DirectedOptimisation) on morbidity (organ damage and infection) and hospital bed days.The Board expects these results will be positive for the Company.LiDCO will announce its preliminary results for the 13 months ended 31stJanuary 2005 on Wednesday 30th March 2005.Notes for Editors:LiDCO is a leading supplier of minimally invasive, computer-based hemodynamicmonitoring equipment and disposables used primarily for the management ofcritical care and cardiovascular risk hospital patients.The Company's current products are: * the LiDCOplus and PulseCO monitors, computer-based platforms for displaying a range of real-time continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; and * the LiDCO disposable for accurately determining cardiac output in a minimally-invasive manner. Application of the LiDCO technology to reduce complications and costs ofsurgery:Post surgical `Goal Directed Optimisation' is an application of the LiDCOplusmonitor. The `Goal' is to target a higher than normal delivery of the oxygencarried by the blood's red cells to the body tissues. Achievement of this`Goal' has been shown to reduce the complications associated with surgery. Toachieve `Goal Directed Optimisation' the LiDCOplus monitor measures theabsolute and beat to beat changing levels of oxygen delivery through use of anarterial line already inserted in a small vessel at the wrist of most majorsurgery patients. The monitor user interface has been specifically designed tohelp the clinician or nurse to rapidly and appropriately administer intravenous fluids and drugs that increase oxygen delivery to levels that ensure therepayment of any oxygen deficit incurred during major surgery. The advantagesof using the LiDCOplus technology are that the oxygen delivery targets can beboth set and achieved minimally invasively using existing staff without the useof more invasive catheters that have additional risks to the patient and coststo the hospital.Enquiries: LiDCO Group Plc 020-7749 1500 Terry O'Brien (CEO) Theresa Wallis (Chairman) Durlacher Ltd 020-7459 3600 Grant Harrison (Head of Corporate Broking) Bankside Consultants Limited Charles Ponsonby (PR) charles.ponsonby@bankside.com 020-7444 4166END